HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice - Wikidata - wikimedia - TriplyDB

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

http://www.wikidata.org/entity/Q37236504

about

Immunoregulatory functions of immune complexes in vaccine and therapy The role of Fc-FcγR interactions in IgG-mediated microbial neutralization Engineering humoral immunity as prophylaxis or therapy Structural insights on the role of antibodies in HIV-1 vaccine and therapy HIV-1 functional cure: will the dream come true?AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth Targeted cytotoxic therapy kills persisting HIV infected cells during ART Latency reversal and viral clearance to cure HIV-1.Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection.Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Early antibody therapy can induce long-lasting immunity to SHIV Antibody 10-1074 suppresses viremia in HIV-1-infected individuals Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success.Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies.Vectored antibody gene delivery for the prevention or treatment of HIV infection.Strategies to guide the antibody affinity maturation process Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

P2860

Q26738396-7DF415C3-6B8E-45F2-9D6C-A81FDBECB501 Q26797466-AC246F08-87B7-436B-862A-846906E249DD Q26800101-9B44E0BE-183E-4FE3-A5BB-4C2E16852E00 Q26829461-B7FE0C59-7AA2-41C1-B4F3-B2C6D465AEC4 Q26865803-467B5553-BCDA-4A5F-A61F-1EBFC05C951D Q27318266-76C546AD-D818-409E-9BB3-B7AD8F2F30ED Q27683553-87698917-CF5B-4B9E-A5AA-7DD904016E2C Q28068946-EDE7946A-BC2E-48D8-81C6-17424DD8FE5B Q28077662-934718F2-8DFF-49F1-9317-9F6EAC93FFBD Q28086826-04C046F1-F00D-4D19-B60B-D8883242A6F3 Q28538598-5434587E-64A2-43FE-85A4-2129CA200D73 Q30248766-40D47C37-512A-41AD-9357-BA3CE701790F Q30393562-02F20697-8F01-4F75-9818-1800C60C63D1 Q33597744-C197FCD4-E1F1-47E5-B761-2AB114EDC193 Q33654409-CF12629B-1A3E-4315-95FD-E934BA031EE0 Q33762877-52086B64-9922-4E67-88D7-158E44251BE2 Q33786443-D023695C-B357-4C88-96CD-4061F090E80E Q33786447-B6404283-78E7-4F8F-B06A-8A953FB6323B Q34049077-2847F780-754A-4283-A401-08B76A55EDC3 Q34174815-5A78B87E-08C4-4C5F-B6E1-78B504F6E2A1 Q34180174-B57DE2E4-DE6C-4FD0-8EAC-BB4F1372944F Q34204325-BF6B8A8D-95F5-4BF8-A084-41661E68A4B4 Q34499013-8B5D1D30-61E5-45A6-A734-B2363CDA071A Q34527469-D12F1907-3275-4950-98F2-F08397328757 Q34527478-8905D843-812C-49FA-975E-D063D6F977F7 Q34531858-468D057B-CB2F-4B3D-872C-14E4BF54105E Q34533041-8D7F3F52-007C-4E07-A0EE-8EF42333BE73 Q34550046-68CDCDD9-AA2B-438E-BF6F-957F947FFBFB Q34583552-6A416C3D-5100-4D5E-BF76-82AF9E691F75 Q34593860-B3E6D4EC-CE69-423B-AE75-7A83F6459A7F Q34594036-6B8EF965-142D-4324-99BF-1B31FEEAD5BB Q34869927-CEAAE0D7-5D6D-42E9-BA52-9BF01C725876 Q35569901-67416425-205B-4664-A780-652FB84F67B6 Q35595846-A82358D8-8B77-4E58-AEB7-160998CEF924 Q35640998-9AF00DA1-90DE-4EC9-9152-D65906C8B1FD Q35664155-FB71167F-EAC9-469A-AE8F-37D81BE89B0A Q35685300-3242A5E4-1FA0-408B-BDC7-C0F4F1967C4B Q35743897-3F522A45-C38F-4087-93C2-61311AD62B8E Q35745432-F6BAB7F1-8D5C-4EAE-A374-CBEA67ED413E Q35827024-2B9236D7-0453-4B24-AC1C-06D9C6633D26

P2860

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

http://www.wikidata.org/entity/Q37236504

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

HIV-1 suppression and durable ...... oviral drugs in humanized mice

@en

HIV-1 suppression and durable ...... viral drugs in humanized mice.

@nl

type

label

HIV-1 suppression and durable ...... oviral drugs in humanized mice

@en

HIV-1 suppression and durable ...... viral drugs in humanized mice.

@nl

prefLabel

HIV-1 suppression and durable ...... oviral drugs in humanized mice

@en

HIV-1 suppression and durable ...... viral drugs in humanized mice.

@nl

P1433

Q37236504-41805E8A-1951-467F-B00E-513A9CB0808F

P1476

Q37236504-E80E5C09-6D76-4744-BCF3-F35166B0DC40

P2093

Q37236504-00F5F09B-CCD3-4750-9367-0F1DBA92BB5D

Q37236504-02DDBAD2-7565-4DDD-A292-AD6E0381A33B

Q37236504-344A363B-8CA7-481F-810A-41CA95D43EA3

Q37236504-59803A0A-5D3A-455B-AC48-49BFDA1F365C

Q37236504-63B449ED-EB47-4008-9A6E-3B1510489D51

Q37236504-7458A2AF-FF3D-43DF-8F73-68250ABACCEE

Q37236504-7697A4C9-31BE-4295-B6BF-054AE86846D8

Q37236504-76D70CA3-38EC-4852-9279-1F7EA096B114

Q37236504-912AFB72-F4E4-423C-840B-3B88D47E7BC4

Q37236504-9EC02C8B-2ECB-48C0-9459-0D088A52B71F

P2860

Q37236504-0359525A-E6DE-4015-9BB6-BD1319451787

Q37236504-046BD069-B9B8-4AFC-9511-7F96B5DABACC

Q37236504-087245AF-62A1-4A0D-ADBE-870EC8E938A5

Q37236504-090CEF02-FC21-4881-8316-0736910A4564

Q37236504-0DEB41C1-5954-4A5F-B3ED-2A98E2911FE0

Q37236504-1F68D2D4-D5F9-4EDF-B05B-0314069A8139

Q37236504-299AA9C0-C994-48D8-9F84-161A428199B5

Q37236504-2AF77696-1A3B-4B69-A9D2-9D5BBA712772

Q37236504-2B366150-81CC-4A02-B9EB-E45F1D6D669A

Q37236504-2DEACEF0-C2E1-4BF6-B4B0-C70FD46495E2

P304

Q37236504-91B51BB1-30C2-48E8-9E40-59902DF5C7EC

P31

Q37236504-5D45173F-FB5F-49B3-BA89-CC827BF040BE

P356

Q37236504-0B902508-DDAC-419F-AE4E-6D7A970C1334

P407

Q37236504-73FC9638-EA20-49AC-BC7E-A0B30CBCF5B2

P433

Q37236504-E2333179-1423-4DFD-8004-7BB05E38FD14

P478

Q37236504-934328D6-CCC5-48D6-A445-4FC25715BB3E

P50

Q37236504-186D9458-4AAF-41D3-AE50-853B411F9AA2

Q37236504-3FBD8E0D-4C7A-4E08-87E9-B833D00451E5

Q37236504-41CEE572-C930-45A0-9C0C-EB1594DC5F78

Q37236504-CA60289A-776A-4A7B-90F2-75A4F7B0E13C

P577

Q37236504-9D889028-6369-421C-9B2D-9535B73845EB

P5875

Q37236504-FD0CF622-D221-48CC-A30A-751E8AEE6EF6

P698

Q37236504-A05E70FF-9599-4015-99AD-FEB257D742C7

P921

Q37236504-315AE095-C56A-4D17-820D-BAD862E0F726

Q37236504-459B8954-F31A-458B-8950-B74AFD7EF22A

Q37236504-C61F0FCC-A518-419D-BFCC-4BB171453C83

P932

Q37236504-E807EFE3-BA17-40D8-A96E-6D3A7F29416E

P356

PNAS.1315295110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

HIV-1 suppression and durable ...... oviral drugs in humanized mice

@en

P2093

Alexander D Gitlin

http://www.w3.org/2001/XMLSchema#string

Alexander Ploss

http://www.w3.org/2001/XMLSchema#string

Anna Tretiakova

http://www.w3.org/2001/XMLSchema#string

Ariel Halper-Stromberg

http://www.w3.org/2001/XMLSchema#string

Charles M Rice

http://www.w3.org/2001/XMLSchema#string

Elena Knops

http://www.w3.org/2001/XMLSchema#string

Eva Billerbeck

http://www.w3.org/2001/XMLSchema#string

Florian Klein

http://www.w3.org/2001/XMLSchema#string

Hildegard Büning

http://www.w3.org/2001/XMLSchema#string

Hugo Mouquet

http://www.w3.org/2001/XMLSchema#string

P2860

Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Redefining the viral reservoirs that prevent HIV-1 eradication

A Blueprint for HIV Vaccine Discovery

The Antibody Response against HIV-1

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

P304

16538-16543

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1315295110

http://www.w3.org/2001/XMLSchema#string

P407

P433

41

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Pamela J. Bjorkman

Michel C. Nussenzweig

Olivier Schwartz

P577

2013-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256666614

http://www.w3.org/2001/XMLSchema#string

P698

24043801

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3799352

http://www.w3.org/2001/XMLSchema#string